Current funding opportunities
Bristol Myers Squibb seeks to align its giving with our commitment to help patients prevail over serious diseases. Consistent with BMS' commitment to advancing health equity for all, BMS does not support programs or initiatives that are not complaint with applicable law. The following areas of interest are eligible for corporate giving and IME requests.
Areas of interest
We accept funding requests within the following therapeutic areas of interest. As areas of interest and funding consideration may change periodically, please consult this website frequently. Please note that international funding opportunities may differ.
For U.S. only: Bristol Myers Squibb is committed to the important work we do to increase health equity for better patient outcomes. We provide funding to support effective solutions with the goal of removing barriers and improving access to quality care for medically underserved and diverse patient populations. As part of our commitment, we accept applications throughout the year to support initiatives focused on our therapeutic areas of interest in one or more of the categories below:
- Disease awareness & education
- Access to quality care
- Patient support services
- Health equity policy and advocacy support
Submit an application to fund a health equity initiative.
YES - Accepting applications | NO - Not accepting applications
| Independent medical education | Other types of grants, giving and corporate sponsorship support (Learn more) | |
| General education - Anticoagulation | YES | YES |
| Stroke prevention / Atrial fibrillation | YES | YES |
| VTE treatment and prevention | YES | YES |
| Hypertrophic cardiomyopathy | YES | YES |
| Secondary stroke prevention | YES | YES |
| Independent medical education | Other types of grants, giving and corporate sponsorship support (Learn more) | |
| Cell therapy - Non-Hodgkin’s lymphoma (DLBCL, FL, MCL, MZL) | YES | YES |
| Cell therapy - Chronic lymphocytic leukemia | YES | YES |
| Cell therapy - Multiple myeloma | YES | YES |
| Cell therapy - Systemic lupus erythematosus (SLE) and Systemic sclerosis (SSc) | YES | YES |
| Cell therapy - Multiple sclerosis (MS) | YES | YES |
| Independent medical education | Other types of grants, giving and corporate sponsorship support | |
| Anemia beta thalassemia | NO | YES |
| Thalassemia (Alpha) | YES | YES |
| Hodgkin Lymphoma | YES | NO |
| CELMoDS- Multiple Myeloma | YES | YES |
| Multiple myeloma (Cell therapy) | YES | YES |
| Myelodysplastic syndrome | YES | YES |
| Myelofibrosis | YES | YES |
| CELMoDS - Non-Hodgkins Lymphoma | YES | YES |
| Non-Hodgkin’s lymphoma (including DLBCL, follicular, mantle cell) (Cell-therapy) | YES | YES |
| Pan Disease | YES | YES |
| Sickle Cell Anemia | YES | YES |
| Independent medical education | Other types of grants, giving and corporate sponsorship support | |
| Psoriasis | YES | YES |
| Rheumatoid arthritis | NO | YES |
| Juvenile idiopathic arthritis | NO | YES |
| Graft vs host disease | NO | YES |
| Kidney transplant | YES | YES |
| Psoriatic arthritis | YES | YES |
| Multiple sclerosis (MS) (general) | NO | YES |
| Multiple sclerosis (MS) (Cell therapy) | YES | YES |
| Systemic lupus erythematosus (general) | NO | YES |
| Systemic lupus erythematosus (Cell therapy) | YES | YES |
| Pulmonary fibrosis/Interstitial lung disease | YES | YES |
| Sjogrens | NO | YES |
| Systemic sclerosis (SSc) (Cell therapy) | YES | YES |
| Idiopathic inflammatory myopathy | YES | YES |
| Independent medical education | Other types of grants, giving and corporate sponsorship support | |
| Alzheimer’s disease | YES | YES |
| Schizophrenia | YES | YES |
| Independent medical education | Other types of grants, giving and corporate sponsorship support | |
| Bladder | YES | YES |
| Biomarker | YES | YES |
| Colorectal | YES | YES |
| Breast | YES | YES |
| Pancreatic | YES | YES |
| GBM | NO | YES |
| Lung | YES | YES |
| Esophageal/gastric | YES | YES |
| Liver (HCC) | YES | YES |
| Melanoma | YES | YES |
| Head & neck | NO | YES |
| RCC | YES | YES |
| Prostate | YES | YES |
| Radiopharpaceuticals | YES | YES |
| Neuroendorcrine | YES | YES |